[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dogwood Therapeutics Inc (DWTX)

Dogwood Therapeutics Inc (DWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,498
  • Shares Outstanding, K 33,630
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,260 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 2
  • High Estimate $-0.13
  • Low Estimate $-0.13
  • Prior Year $-1.99
  • Growth Rate Est. (year over year) +93.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4500 +3.45%
on 05/07/26
1.9800 -24.24%
on 05/14/26
+0.0600 (+4.17%)
since 05/05/26
3-Month
1.2800 +17.19%
on 04/29/26
3.5000 -57.14%
on 03/10/26
-1.3600 (-47.55%)
since 03/05/26
52-Week
1.2800 +17.19%
on 04/29/26
9.5000 -84.21%
on 09/29/25
-3.3850 (-69.29%)
since 06/05/25

Most Recent Stories

More News
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics Announces First Quarter 2026 Financial Results

-  Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy,...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood  licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy,...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

 - Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement   Offerings priced at-the-market under Nasdaq rules   ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE)...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

- Halneuron ® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below...

DWTX : 1.5000 (-10.71%)
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron ® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured...

DWTX : 1.5000 (-10.71%)

Business Summary

Dogwood Therapeutics Inc. is a biopharmaceutical company. It engages in developing a new class of non-opioid analgesics. The company focuses on the development of Halneuron, IMC-1 and IMC-2. Dogwood Therapeutics Inc., formerly known as Virios Therapeutics Inc., is based in Alpharetta, GA.

See More

Key Turning Points

3rd Resistance Point 1.7333
2nd Resistance Point 1.6867
1st Resistance Point 1.5933
Last Price 1.5000
1st Support Level 1.4533
2nd Support Level 1.4067
3rd Support Level 1.3133

See More

52-Week High 9.5000
Fibonacci 61.8% 6.3600
Fibonacci 50% 5.3900
Fibonacci 38.2% 4.4200
Last Price 1.5000
52-Week Low 1.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.